The randomized, double-blind phase I study of the pandemic vaccine deltaFLU will be run at the Department of Clinical Pharmacology, Medical University of Vienna. The aim of Phase I study is to analyze the safety and efficacy of the vaccine in healthy volunteers.
According to the company, this novel generation of a live-attenuated vaccine based on the deletion of the NS1 gene has shown superior preclinical data.
Thomas Muster, founder and CEO of Avir Green Hills, said: “Our vaccine lacks the pathogenicity factor NS1. Due to this deletion, the vaccine is likely to show a superior safety profile. We are confident that the pandemic deltaFLU vaccine will be tolerated even at high doses.”